Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
Tuesday, October 22, 2024Alvotech and Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd today announced that the US Food and Drug Administration FDA has approved SELARSDI ustekinumabaekn in a new presentation mg mL mgmL solution in a singledose vial...
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
Monday, October 21, 2024Angelini Pharma part of the privately owned Angelini Industries and Cureverse Inc an earlystage research and development company announced today that they entered into an exclusive global option agreement for the development and commercialization of...
Wainzua (eplontersen) recommended for approval in the EU by CHMP for the treatment of adult patients with polyneuropathy associated with hereditary transthyretin-mediated amyloidosis
Monday, October 21, 2024AstraZeneca and Ionis Wainzua eplontersen has been recommended for approval by the Committee for Medicinal Products for Human Use CHMP in the European Union EU for the treatment of hereditary transthyretinmediated amyloidosis in adult patients with s...
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study
Saturday, October 19, 2024Roche announced today positive topline oneyear results from the openlabel singlearm phase IV ELEVATUM study evaluating Vabysmo faricimab for the treatment of diabetic macular edema DME in people from racial and ethnic groups that are often underrepre...
Long-term efficacy and safety profile of Eylea™ 8 mg with extended dosing intervals in diabetic macular edema confirmed at three years
Saturday, October 19, 2024Bayer and its collaboration partner Regeneron presented results from the openlabel extension study of the clinical trial PHOTON in patients with diabetic macular edema DME at three years in a latebreaking session at the American Academy of Ophthalmol...
OSE Immunotherapeutics Introduces Novel Bispecific “Cis-Unmasking” Technology for Cytokine Drug Design with Improved Therapeutic Index
Friday, October 18, 2024OSE Immunotherapeutics SApresents OSECYTOMASK its novel bispecific CisUnmasking cytokine technology during selected oral presentations for international conferences
Sanofi and Orano join forces to develop next-generation radioligand medicines
Friday, October 18, 2024Sanofi and Orano Med a subsidiary of the Orano Group and a pioneer in the development of targeted alphatherapies in oncology have entered into an agreement to combine their expertise in the fight against rare cancers and further accelerate the develo...
Alhemo® recommended for European approval as first once-daily subcutaneous prophylactic treatment for people living with haemophilia A or B with inhibitors
Friday, October 18, 2024Novo Nordisk today announced that the European Medicines Agencys EMA Committee for Medicinal Products for Human Use CHMP has adopted a positive opinion recommending approval of Alhemo concizumab as the first oncedaily subcutaneous prophylactic treatm...
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
Thursday, October 17, 2024CSL Vifor and Travere Therapeutics Inc today announced that Swissmedic has granted temporary marketing authorization for FILSPARI for the treatment of adults with primary IgA nephropathy IgAN with a urine protein excretion
Exscientia Achieves Milestones for Two Programmes in Sanofi Collaboration
Wednesday, October 16, 2024Exscientia plc announced the advancement of two additional discovery programmes within its collaboration with Sanofi with Exscientia receiving an aggregate of million in milestone payments Both lead compounds have met the product profile requirement...
